Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
Ipsen voluntarily withdrew tazemetostat in follicular lymphoma and epithelioid sarcoma after 18 of 318 SYMPHONY-1 participants developed hematologic second primary malignancies, including three deaths.
Hematology/Oncology May 26th 2026
Hematology Advisor
“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”
Hematology August 18th 2025
Clinical Advances in Hematology & Oncology
Luspatercept demonstrates superior efficacy in achieving transfusion independence for patients with low-risk MDS compared to traditional erythropoiesis-stimulating agents.
Hematology October 21st 2024
Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.
Hematology/Oncology April 8th 2024
Oncology Learning Network
Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.
Hematology October 9th 2023
ReachMD
Enhance your clinical decision-making skills in the management of ESA-refractory LR-MDS. Register now for actionable insights and the latest research findings.
Clinical Pharmacology September 5th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS